Insider Selling: Acceleron Pharma Inc (NASDAQ:XLRN) VP Sells $37,244.80 in Stock

Share on StockTwits

Acceleron Pharma Inc (NASDAQ:XLRN) VP Adam M. Veness sold 824 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $45.20, for a total transaction of $37,244.80. Following the completion of the sale, the vice president now directly owns 16,124 shares of the company’s stock, valued at $728,804.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of Acceleron Pharma stock opened at $46.20 on Friday. Acceleron Pharma Inc has a 52-week low of $37.01 and a 52-week high of $59.59. The company has a quick ratio of 17.11, a current ratio of 17.11 and a debt-to-equity ratio of 0.05. The company’s 50-day simple moving average is $44.35 and its 200-day simple moving average is $42.89. The firm has a market cap of $2.41 billion, a price-to-earnings ratio of -17.84 and a beta of 1.23.

Acceleron Pharma (NASDAQ:XLRN) last issued its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10). Acceleron Pharma had a negative return on equity of 29.51% and a negative net margin of 318.84%. The firm had revenue of $27.67 million for the quarter, compared to analyst estimates of $28.72 million. During the same quarter last year, the firm earned ($0.63) earnings per share. The company’s revenue was up 649.9% compared to the same quarter last year. Equities research analysts anticipate that Acceleron Pharma Inc will post -2.33 EPS for the current year.

Institutional investors have recently modified their holdings of the company. Brown Advisory Inc. increased its stake in shares of Acceleron Pharma by 0.6% during the second quarter. Brown Advisory Inc. now owns 365,844 shares of the biopharmaceutical company’s stock worth $15,030,000 after acquiring an additional 2,003 shares during the period. TimesSquare Capital Management LLC increased its stake in shares of Acceleron Pharma by 29.5% during the first quarter. TimesSquare Capital Management LLC now owns 920,715 shares of the biopharmaceutical company’s stock worth $42,878,000 after acquiring an additional 209,900 shares during the period. MetLife Investment Advisors LLC increased its stake in shares of Acceleron Pharma by 10.9% during the first quarter. MetLife Investment Advisors LLC now owns 19,308 shares of the biopharmaceutical company’s stock worth $899,000 after acquiring an additional 1,902 shares during the period. Westfield Capital Management Co. LP increased its stake in shares of Acceleron Pharma by 6.5% during the first quarter. Westfield Capital Management Co. LP now owns 1,377,123 shares of the biopharmaceutical company’s stock worth $64,133,000 after acquiring an additional 84,410 shares during the period. Finally, Asymmetry Capital Management L.P. increased its stake in shares of Acceleron Pharma by 62.3% during the first quarter. Asymmetry Capital Management L.P. now owns 30,125 shares of the biopharmaceutical company’s stock worth $1,403,000 after acquiring an additional 11,561 shares during the period. Institutional investors and hedge funds own 90.12% of the company’s stock.

A number of equities research analysts have recently commented on the stock. ValuEngine raised shares of Acceleron Pharma from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 8th. JPMorgan Chase & Co. reduced their target price on shares of Acceleron Pharma from $61.00 to $58.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Morgan Stanley set a $53.00 target price on shares of Acceleron Pharma and gave the company a “hold” rating in a report on Monday, July 15th. BidaskClub cut shares of Acceleron Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. Finally, Goldman Sachs Group reaffirmed a “neutral” rating and issued a $54.00 target price on shares of Acceleron Pharma in a report on Wednesday, May 29th. Six investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $60.10.

Acceleron Pharma Company Profile

Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis.

Further Reading: How analysts view the yield curve

Insider Buying and Selling by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.